Web Exclusives

Web Exclusives | February 19, 2019
On February 12, 2019, the US Food and Drug Administration (FDA) granted approval for daratumumab (Darzalex; Janssen), a CD38-directed antibody, to be given in a split-dosing regimen to patients with multiple myeloma (MM). Darzalex is the first and only CD38-directed antibody to receive regulatory approval for the treatment of patients with MM and is the first to be approved for the split-dosing regimen. This new regimen gives patients and healthcare providers the option to split the first dose of Darzalex over the course of 2 consecutive days, which has the benefit of shortening the duration of the first infusion.
Web Exclusives | October 2, 2018
The Academy of Oncology Nurse & Patient Navigators (AONN+) is pleased to announce Dr Jill Biden as the Keynote Speaker for the Ninth Annual Navigation & Survivorship Conference.
Web Exclusives | May 15, 2018
These results make quizartinib the first FLT3 inhibitor to demonstrate such improvement over chemotherapy in this patient population.

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code